+33 1 76 70 47 90
/
creativ@creativ-ceutical.com
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
[PSY115] How Should We Value Orphan Drugs? Suggestions From A Large Public Opinion Survey
Home
Publications
[PSY115] How Should We Value Orphan Drugs? Suggestions From A Large Public Opinion Survey
Back Home
[PSY115] How Should We Value Orphan Drugs? Suggestions From A Large Public Opinion Survey
2017 Value in Health
Korchagina, D. | Toumi, M. | Aballea, S. | Millier, A. | Falissard, B. |
Volume: 20, Issue: 9, Pages: A564-A565,
https://www.doi.org/10.1016/j.jval.2017.08.942
